Skip to main content Accessibility help
×
×
Home

The clinical challenges of akathisia

  • James B. Lohr (a1) (a2), Carolyn A. Eidt (a1) (a2), Areej Abdulrazzaq Alfaraj (a1) and Mounir A. Soliman (a1)

Abstract

Akathisia is one of the most vexing problems in neuropsychiatry. Although it is one of the most common side effects of antipsychotic medications, it is often difficult to describe by patients, and is difficult to diagnose and treat by practitioners. Akathisia is usually grouped with extrapyramidal movement disorders (ie, movement disorders that originate outside the pyramidal or corticospinal tracts and generally involve the basal ganglia). Yet, it can present as a purely subjective clinical complaint, without overt movement abnormalities. It has been subtyped into acute, subacute, chronic, tardive, withdrawal-related, and “pseudo” forms, although the distinction between many of these is unclear. It is therefore not surprising that akathisia is generally either underdiagnosed or misdiagnosed, which is a serious problem because it can lead to such adverse outcomes as poor adherence to medications, exacerbation of psychiatric symptoms, and, in some cases, aggression, violence, and suicide. In this article, we will attempt to address some of the confusion surrounding the condition, its relationship to other disorders, and differential diagnosis, as well as treatment alternatives.

Copyright

Corresponding author

*Address for correspondence: James B. Lohr, Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA. (Email: jlohr@ucsd.edu)

Footnotes

Hide All

We would like to thank Dr. Stephen Stahl and the staff of the Neuroscience Education Institute for their assistance in preparing this article. This activity is supported by an unrestricted educational grant from Vanda Pharmaceuticals Inc.

Footnotes

References

Hide All
1.Berrios, GE. Lad Haskovec and akathisia: an introduction. Hist Psychiatry. 1995; 6(22): 243245.
2.Mohr, P, Volavka, J. Ladislav Haskovec and akathisia: 100th anniversary. Br J Psychiatry. 2002; 181(6): 537.
3.Sachdev, P. The development of the concept of akathisia: a historical overview. Schizophr Res. 1995; 16(1): 3345.
4.Baden, EY, Prodany, K, Wiener, SW, Hoffman, RS. Diphenhydramine in the treatment of akathesia induced by prochlorperazine. J Emerg Med. 2005; 28(3): 347348.
5.Keckich, WA. Neuroleptics: violence as a manifestation of akathisia. JAMA. 1978; 240(20): 2185.
6.Leong, GB, Silva, JA. Neuroleptic-induced akathisia and violence: a review. J Forensic Sci. 2003; 48(1): 187189.
7.Seemuller, F, Lewitzka, U, Bauer, M, et al. The relationship of akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. Pharmacopsychiatry. 2012; 45(7): 292296.
8.Hansen, L. A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol. 2001; 16(7): 495505.
9.Galynker, II, Nazarian, D. Akathisia as violence. J Clin Psychiatry. 1997; 58(1): 3132.
10.Lipinski, JF Jr, Mallya, G, Zimmerman, P, Pope, HG Jr.Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry. 1989; 50(9): 339342.
11.Raskin, DE. Akathisia: a side effect to be remembered. Am J Psychiatry. 1972; 129(3): 345347.
12.Van Putten, T. The many faces of akathisia. Compr Psychiatry. 1975; 16(1): 4347.
13.Duncan, EJ, Adler, LA, Stephanides, M, Sanfilipo, M, Angrist, B. Akathisia and exacerbation of psychopathology: a preliminary report. Clin Neuropharmacol. 2000; 23(3): 169173.
14.Nair, CJ, Josiassen, RC, Abraham, G, Stanilla, JK, Tracy, JI, Simpson, GM. Does akathisia influence psychopathology in psychotic patients treated with clozapine? Biol Psychiatry. 1999; 45(10): 13761383.
15.Peitl, MV, Proloscic, J, Blazevic-Zelic, S, Skarpa-Usmiani, I, Peitl, V. Symptoms of agitated depression and/or akathisia. Psychiatr Danub. 2011; 23(1): 108110.
16.Lohr, JB, Wisniewski, AA. Movement disorders: a neuropsychiatric approach. New York: Guildford Press; 1987.
17.Lohr, JB, Browning, JA. Movement disorders in neuropsychiatry. Curr Opin Psychiatry. 1996; 9(1): 8588.
18.Hirose, S. Restlessness in suboccipital muscles as a manifestation of akathisia. Psychiatry Clin Neurosci. 2001; 55(1): 8182.
19.Yamashita, H, Horiguchi, J, Mizuno, S, Kuramoto, Y, Yamawaki, S, Inami, Y. A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep. Psychiatry Clin Neurosci. 1999; 53(2): 291293.
20.Bratti, IM, Kane, JM, Marder, SR. Chronic restlessness with antipsychotics. Am J Psychiatry. 2007; 164(11): 16481654.
21.Sachdev, P. The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Schizophr Bull. 1995; 21(3): 451461.
22.Lang, AE. Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. Mov Disord. 1994; 9(2): 188192.
23.Bhidayasiri, R, Boonyawairoj, S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J. 2011; 87(1024): 132141.
24.Nishikawa, T, Koga, I, Uchida, Y, Tanaka, M. Treatment of tardive akathisia with clonidine. Kurume Med J. 1990; 37(3): 185187.
25.Munetz, MR, Cornes, CL. Akathisia, pseudoakathisia and tardive dyskinesia: clinical examples. Compr Psychiatry. 1982; 23(4): 345352.
26.Stubbs, JH, Halstead, SM. Pseudoakathisia: a review and two case reports. Compr Psychiatry. 2000; 41(1): 7072.
27.Bing, R. Textbook of Nervous Diseases. St. Louis, MO: C.V. Mosby; 1939.
28.Kumar, R, Sachdev, PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry. 2009; 22(3): 293299.
29.Kane, JM, Fleischhacker, WW, Hansen, L, Perlis, R, Pikalov, A 3rd, Assuncao-Talbott, S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009; 70(5): 627643.
30.Kemp, DE, Gilmer, WS, Fleck, J, Straus, JL, Dago, PL, Karaffa, M. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(2): 574577.
31.Saddichha, S, Kumar, R, Babu, GN, Chandra, P. Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient. J Clin Pharmacol. 2012; 52(9): 14481449.
32.Spielmans, GI, Berman, MI, Linardatos, E, Rosenlicht, NZ, Perry, A, Tsai, AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013; 10(3): e1001403.
33.Oh, GH, Yu, J-C, Choi, K-S, Joo, E-J, Jeong, S-H. Simultaneous comparison of efficacy and tolerability of second-generation antipsychotics in schizophrenia: mixed-treatment comparison analysis based on head-to-head trial data. Psychiatry Investig. 2015; 12(1): 4654.
34.Stahl, SM. Role of alpha1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr. 2013; 18(6): 285288.
35.Citrome, L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011; 72(Suppl 1): 1923.
36.Dargani, NV, Malhotra, AK. Safety profile of iloperidone in the treatment of schizophrenia. Expert Opin Drug Saf. 2014; 13(2): 241246.
37.Tarazi, FI, Stahl, SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012; 13(13): 19111922.
38.Caccia, S, Pasina, L, Nobili, A. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther. 2010; 4: 3348.
39.Grover, S, Sahoo, S. Clozapine induced akathisia: a case report and review of the evidence. Indian J Pharmacol. 2015; 47(2): 234235.
40.Schneider, C, Corrigall, R, Hayes, D, Kyriakopoulos, M, Frangou, S. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry. 2014; 29(1): 110.
41.Cohen, BM, Keck, PE, Satlin, A, Cole, JO. Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry. 1991; 29(12): 12151219.
42.Wright, MT. Antiemetics, akathisia, and pregnancy. Psychosomatics. 2007; 48(6): 461466.
43.Kawanishi, C, Onishi, H, Kato, D, et al. Unexpectedly high prevalence of akathisia in cancer patients. Palliat Support Care. 2007; 5(4): 351354.
44.Adler, LA, Angrist, BM. Paroxetine and akathisia. Biol Psychiatry. 1995; 37(5): 336337.
45.Baldassano, CF, Truman, CJ, Nierenberg, A, Ghaemi, SN, Sachs, GS. Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry. 1996; 37(2): 122124.
46.Bonnet-Brilhault, F, Thibaut, F, Leprieur, A, Petit, M. A case of paroxetine-induced akathisia and a review of SSRI-induced akathisia. Eur Psychiatry. 1998; 13(2): 109111.
47.Grover, S, Valaparla, VL. Venlafaxine induced akathisia: a case report. Indian J Pharmacol. 2014; 46(6): 660661.
48.Hawthorne, JM, Caley, CF. Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother. 2015; 49(10): 11361152.
49.Koliscak, LP, Makela, EH. Selective serotonin reuptake inhibitor-induced akathisia. J Am Pharm Assoc (2003). 2009; 49(2): e28e36; quiz e37–28.
50.Lambert, MT, Trutia, C, Petty, F. Extrapyramidal adverse effects associated with sertraline. Prog Neuropsychopharmacol Biol Psychiatry. 1998; 22(5): 741748.
51.Lane, RM. SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol. 1998; 12(2): 192214.
52.Olivera, AA. A case of paroxetine-induced akathisia. Biol Psychiatry. 1996; 39(10): 910.
53.Vandel, P, Bonin, B, Leveque, E, Sechter, D, Bizouard, P. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol. 1997; 7(3): 207212.
54.Gill, HS, DeVane, CL, Risch, SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol. 1997; 17(5): 377389.
55.Riesselman, A, El-Mallakh, RS. Akathisia with azithromycin. Ann Pharmacother. 2015; 49(5): 609.
56.Sachdev, P. The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Schizophr Bull. 1995; 21(3): 431449.
57.Asser, A, Taba, P. Psychostimulants and movement disorders. Front Neurol. 2015; 6: 75.
58.Stacy, M. Nonmotor symptoms in Parkinson’s disease. Int J Neurosci. 2011; 121(Suppl 2): 917.
59.Pappa, S, Dazzan, P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med. 2009; 39(7): 10651076.
60.Brüne, M. The incidence of akathisia in bipolar affective disorder treated with neuroleptics—a preliminary report. J Affect Disord. 1999; 53(2): 175177.
61.De Fruyt, J, Deschepper, E, Audenaert, K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol. 2012; 26(5): 603617.
62.Kane, JM, Barnes, TR, Correll, CU, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol. 2010; 24(7): 10191029.
63.Miller, CH, Hummer, M, Oberbauer, H, Kurzthaler, I, DeCol, C, Fleischhacker, WW. Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacol. 1997; 7(1): 5155.
64.Nordström, P, Michaëlsson, K, Gustafson, Y, Nordström, A. Traumatic brain injury and young onset dementia: a nationwide cohort study. Ann Neurol. 2014; 75(3): 374381.
65.Stewart, JT. Akathisia following traumatic brain injury: treatment with bromocriptine. J Neurol Neurosurg Psychiatry. 1989; 52(10): 12001201.
66.Brown, K, Glen, S, White, T. Low serum iron status and akathisia. Lancet. 1987; 329(8544): 12341236.
67.Krieger, J, Schroeder, C. Iron, brain and restless legs syndrome. Sleep Med Rev. 2001; 5(4): 277286.
68.Chong, SA, Mythily, , Remington, G. Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia. Schizophr Res. 2003; 59(1): 6771.
69.Akagi, H, Kumar, TM. Lesson of the week: akathisia: overlooked at a cost. BMJ. 2002; 324(7352): 15061507.
70.Hirose, S. The causes of underdiagnosing akathisia. Schizophr Bull. 2003; 29(3): 547558.
71.Stahl, SM. Akathisia and tardive dyskinesia: changing concepts. Arch Gen Psychiatry. 1985; 42(9): 915917.
72.Weiden, PJ, Mann, JJ, Haas, G, Mattson, M, Frances, A. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry. 1987; 144(9): 11481153.
73.Madruga-Garrido, M, Mir, P. Tics and other stereotyped movements as side effects of pharmacological treatment. In Davide M, Andrea EC eds International Review of Neurobiology. Vol 112. London: Academic Press; 2013: 481494.
74.Weiden, P, Bruun, R. Worsening of Tourette’s disorder due to neuroleptic-induced akathisia. Am J Psychiatry. 1987; 144(4): 504505.
75.Fountoulakis, KN, Samara, M, Siapera, M, Iacovides, A. Tardive Tourette-like syndrome: a systematic review. Int Clin Psychopharmacol. 2011; 26(5): 237242.
76.Stahl, SM. Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration. Am J Psychiatry. 1980; 137(10): 12671269.
77.Burkhard, PR. Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord. 2014; 20(Suppl 1): S108S112.
78.Dayalu, P, Chou, KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother. 2008; 9(9): 14511462.
79.Mihanovic, M, Bodor, D, Kezic, S, Restek-Petrovic, B, Silic, A. Differential diagnosis of psychotropic side effects and symptoms and signs of psychiatric disorders. Psychiatr Danub. 2009; 21(4): 570574.
80.Rodnitzky, RL. Drug-induced movement disorders. Clin Neuropharmacol. 2002; 25(3): 142152.
81.Sachdev, PS. Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am. 2005; 28(1): 255274.
82.Kahn, EM, Munetz, MR, Davies, MA, Schulz, SC. Akathisia: Clinical phenomenology and relationship to tardive dyskinesia. Compr Psychiatry. 1992; 33(4): 233236.
83.Ekbom, KA. Asthenia crurum paraesthetica («irritable legs»). Acta Med Scand. 1944; 118(1–3): 197209.
84.Trenkwalder, C, Paulus, W, Walters, AS. The restless legs syndrome. Lancet Neurol. 2005; 4(8): 465475.
85.Angelini, M, Negrotti, A, Marchesi, E, Bonavina, G, Calzetti, S. A study of the prevalence of restless legs syndrome in previously untreated Parkinson’s disease patients: absence of co-morbid association. J Neurol Sci. 2011; 310(1–2): 286288.
86.Bhalsing, K, Suresh, K, Muthane, UB, Pal, PK. Prevalence and profile of restless legs syndrome in Parkinson’s disease and other neurodegenerative disorders: a case-control study. Parkinsonism Relat Disord. 2013; 19(4): 426430.
87.Möller, JC, Unger, M, Stiasny-Kolster, K, Oertel, WH. Restless legs syndrome (RLS) and Parkinson’s disease (PD)—related disorders or different entities? J Neurol Sci. 2010; 289(1–2): 135137.
88.Nomura, T, Inoue, Y, Nakashima, K. Clinical characteristics of restless legs syndrome in patients with Parkinson’s disease. J Neurol Sci. 2006; 250(1–2): 3944.
89.Rijsman, RM, Schoolderman, LF, Rundervoort, RS, Louter, M. Restless legs syndrome in Parkinson’s disease. Parkinsonism Relat Disord. 2014; 20(Suppl 1): S5S9.
90.Blaisdell, GD. Akathisia: a comprehensive review and treatment summary. Pharmacopsychiatry. 1994; 27(4): 139146.
91.Poewe, W, Hogl, B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson’s disease. Neurology. 2004; 63(8 Suppl 3): S12S16.
92.Linazasoro, G, Massó, JFM, Suárez, JA. Nocturnal akathisia in Parkinson’s disease: treatment with clozapine. Mov Disord. 1993; 8(2): 171174.
93.Takahashi, M, Ikeda, J, Tomida, T, Hirata, K, Hattori, N, Inoue, Y. Daytime symptoms of restless legs syndrome—clinical characteristics and rotigotine effectiveness. Sleep Med. 2015; 16(7): 871876.
94.Walters, AS, Hening, W, Rubinstein, M, Chokroverty, S. A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep. 1991; 14(4): 339345.
95.Marsden, CD, Jenner, P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med. 1980; 10(1): 5572.
96.Eisensehr, I, Ehrenberg, BL, Noachtar, S. Different sleep characteristics in restless legs syndrome and periodic limb movement disorder. Sleep Med. 2003; 4(2): 147152.
97.Stahl, SM, Loonen, AJ. The mechanism of drug-induced akathisia. CNS Spectr. 2011; 16(1): 710.
98.Rios Romenets, S, Dauvilliers, Y, Cochen De Cock, V, et al. Restless legs syndrome outside the blood–brain barrier—exacerbation by domperidone in Parkinson’s disease. Parkinsonism Relat Disord. 2013; 19(1): 9294.
99.Barnes, TRE. The Barnes Akathisia Rating Scale–Revisited. J Psychopharmacol. 2003; 17(4): 365370.
100.Lima, AR, Weiser, KV, Bacaltchuk, J, Barnes, TR. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2004; (1): CD003727.
101.Rathbone, J, Soares-Weiser, K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2006; (4): CD003727.
102.Baskak, B, Atbasoglu, EC, Ozguven, HD, Saka, MC, Gogus, AK. The effectiveness of intramuscular biperiden in acute akathisia: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2007; 27(3): 289294.
103.Lima, AR, Bacalcthuk, J, Barnes, TR, Soares-Weiser, K. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2004; (4): CD001946.
104.Poyurovsky, M. Acute antipsychotic-induced akathisia revisited. Br J Psychiatry. 2010; 196(2): 8991.
105.Berk, M, Copolov, D, Dean, O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008; 64(5): 361368.
106.Guay, DRP. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010; 8(4): 331373.
107.Jankovic, J, Clarence-Smith, K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011; 11(11): 15091523.
108.Fehr, C, Dahmen, N, Klawe, C, Eicke, M, Szegedi, A. Piracetam in the treatment of tardive dyskinesia and akathisia: a case report. J Clin Psychopharmacol. 2001; 21(2): 248249.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed